Carisoprodol/Meprobamate, Screen and Confirmation, Urine
Use
This test is intended for the qualitative and quantitative determination of Carisoprodol and its metabolite Meprobamate in urine. It is primarily used for pain management and monitoring compliance with prescribed therapy. It helps in identifying potential misuse or abuse of these medications, aiding healthcare providers in making informed decisions regarding patient care.
Special Instructions
This assay is intended for pain management purposes only. It is specifically designed for healthcare providers monitoring compliance with prescribed medication regimens and is not suitable for workplace drug testing. The test does not comply with regulatory standards required for occupational drug testing programs. Additional charges may apply for confirmation tests if initial screenings are positive.
Limitations
The test has been developed and validated by LabCorp for clinical applications. However, it has not received clearance or approval from the US Food and Drug Administration (FDA), and its use is limited to professional healthcare settings with the understanding of these constraints. False positives or negatives may occur due to cross-reactivity with other substances or improper specimen handling. The test's ability to detect all possible substances related to Carisoprodol and Meprobamate use might be limited.
Methodology
Immunoassay (Other)
Biomarkers
LOINC Codes
- 58370-8
- 58370-8
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
20 mL
Minimum Volume
Not provided
Container
Plastic urine container
Storage Instructions
Maintain specimen at room temperature. If arrival at lab will extend beyond seven days, refrigerate.